Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)

Condition:   Malignant Neoplasms of Lip Oral Cavity and Pharynx
Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Behavioral: Questionnaire;   Procedure: Surgery;   Drug: Chemotherapy;   Radiation: Radiation Therapy
Sponsors:   M.D. Anderson Cancer Center;   AstraZeneca;   Stiefel, a GSK Company
Not yet recruiting - verified May 2017

http://ift.tt/2prqSJS